b c d a kDa 220 50 (a-b) C2C12 myofibers were treated with or without IFNγ/TNFα for 24 hours in the presence or absence of 0.05µM Epi. (a) Immunofluorescence analysis was performed using antibodies against myoglobin and MyHC. Bars, 20µm. (b) Western blot analysis of MyHC protein levels in myofibers treated with or without IFNγ/TNFα in the presence or absence of Epi. Tubulin protein levels are included as a loading control.
Figure S2: Injection of BALB/c mice with C26 adenocarcinoma cells triggers tumour growth leading to iNOS expression and the loss of MyoD mRNA.
(a-e) (a) Body weight of mice (subsequent to the removal of the tumour) and the mass of the gastrocnemius (b) were determined at 19 days post-C26-injection and plotted +/-S.E.M. from 8 and 9 mice respectively for saline control and C26 injected mice. *P<0.05, **P<0.01 (Student's t-test) . (c) The expression of MyoD mRNA in the gastrocnemius muscle is decreased in C26-injected mice. The gastrocnemius muscle was isolated from mice 19 days post injection with or without C26 cells. RNA harvested from the muscle was analyzed by slot blot to determine MyoD mRNA levels. These levels were quantified using the ImageQuant software, standardized against 18S rRNA levels and plotted +/-the S.E.M. ***P<0.001 (Student's t-test). (d) Total protein extracts from the gastrocnemius muscles of C26-injected mice were prepared and used for western blot analysis to determine the levels of iNOS protein. (e) The expression of iNOS and MyoD mRNA was determined over time using a slot blot analysis on total mRNAs prepared from the gastrocnemius muscle of BALB/c mice injected with or without C26 cells. The steady state levels of the iNOS and MyoD messages was assessed every third day until eighteen days post C26 injection. (f-g) The iNOS (f) and MyoD (g) mRNA levels were quantified using the ImageQuant software, standardized against 18S rRNA levels and plotted +/-the S.E.M from 3 mice per time point. Weight of gastrocnemius muscles isolated from mice 6, 9, 13, 18 and 21 days post-C26 injection. 20 µg/kg PatA was injected into these mice on day 13 and every second day thereafter until the end of the experiment. The weight of the muscles (obtained from a range of 3-6 mice) were plotted +/-S.E.M. *P<0.05, **P<0.01 (Student's t-test). The release of nitric oxide by IFNγ/TNFα-treated myofibers is downregulated by PatA in a dose dependent manner. Nitric oxide (NO) release by C2C12 myofibers was detected using the GREISS reagent 24 hours after treatment with or without the doses of Pat described above in the presence or absence of IFNγ /TNFα. NO levels were plotted +/-the S.E.M from three independent experiments. ***P<0.001, (Student's t-test).
Figure S4: C26-tumours induced muscle loss in BALB/c mice starts as early as day 13 post injection of C26-adenocarcinoma cells.

Figure S9: PatA has no effect on the expression of IL-6 in cytokine-treated myofibers.
(a) Total mRNA was harvested from C2C12 myofibers treated with or without IFNγ/TNFα for 24h in the presence or absence of PatA and analyzed by RT-qPCR to determine IL-6 mRNA levels that were standardized against RPL32 mRNA levels. 
Supplementary Methods
Luciferase Reporter Experiments:
The iNOS and MyoD 5'UTRs were generated by RT-PCR from total RNA isolated from C2C12 myofibers using the following primers: The Rluc control PCR fragment was generated using the pCREL vector and the following primers:
RLuc-F 5 '-TAA TAC GAC TCA CTA TAG GGC CAC TTT GCC TTT CTC TCC-3'   RLuc-R 5'-TTT TTT TTT TTT TTT TTT TTT TTT GTG AGT CGT ATT AAT TTC GC-3'. cRNA encoding the iNOS and MyoD 5'UTR fused to the firefly luciferase as well as the control renilla luciferase were generated from the iNOS-FLuc, MyoD-FLuc and Rluc PCR fragments respectively using the mMESSAGE mMACHINE® T7 kit (Ambion) as per the manufacturer's instructions. 0.5µg of each Fluc reporter cRNAs were co-transfected with 0.5µg control Rluc cRNA (using Lipofectamine transfection reagent, Invitrogen) into C2C12 myoblasts that were subsequently treated with or without IFNγ/TNFα and/or PatA. Luciferase activity was then measured using a luciferase assay system (Promega) with a luminometer following the manufacturer's instructions.
Primers for in situ hybridization experiments:
The iNOS, MyoD and Myogenin mRNAs were then detected by in situ hybridization using the following primers. The sense and anti-sense probes were generated from PCR fragments using the
